Loading
Sentiment · FY2026 Q2
As of FY2026 Q1, the Tellvest earnings-call sentiment score for Regeneron Pharmaceuticals (REGN) is 7/10.
Regeneron delivered Q1 total revenues up 19% year-over-year with non-GAAP diluted EPS of $9.47 growing 15%, as Dupixent global net sales increased 31% at constant currency to $4.9 billion. EYLEA HD physician adoption accelerated, and the Libtayo oncology franchise continued expanding. GAAP gross margin guidance was updated to 77-78% due to a temporary Limerick manufacturing disruption, while a most-favored-nation drug pricing agreement was reached.
Scored from Regeneron Pharmaceuticals’s FY2026 Q1 earnings call. The newest quarter is available with Tellvest Pro.
Full Pro access for 30 days when you create a free account. No credit card required.
All prior quarters are free.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $3.79B | +10.3% | $8.06 | -20.9% | 26.1% | 24.2% | $996M |
| FY2025 Q1 | $3.03B | -3.7% | $7.27 | +15.9% | 19.5% | 26.7% | $774M |
| FY2025 Q2 | $3.68B | +3.6% | $12.81 | +3.2% | 29.4% | 37.9% |
| $968M |
| FY2025 Q3 | $3.75B | +0.9% | $13.62 | +18.0% | 27.3% | 38.9% | $1.42B |
| FY2025 Q4 | $3.88B | +2.5% | $7.86 | -2.5% | 22.7% | 21.7% | $922M |
| FY2026 Q1 | $3.61B | +19.0% | $6.75 | -7.2% | 17.8% | 20.2% | $848M |
| FY2026 Q2 | $4.29B | +16.7% | $12.23 | -4.5% | 30.1% | 30.2% | $573M |